Physicians' Academy for Cardiovascular Education

OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition

Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein



Prof. John Kastelein, AMC, Amsterdam, The Netherlands comments on the results of the OSLER program with PCSK9 inhibitor evolocumab and provides a perspective on the therapeutic potential of PCSK9 inhibitors. Prof Kastelein is looking forward to the large scale clinical outcome trial FOURIER to confirm the results.

 

News • 16-3-2015

PCSK9 inhibitor halves CV endpoints after a year of treatment

ACC 2015 PCSK9 inhibition with evolocumab halves the number of major CV outcomes in the open label OSLER extension programme. Treatment with evolocumab was safe, also at very low LDL-c levels.

3 minute education • 15-3-2015, ACC 2015, San Diego, Marc Sabatine, MD Boston

OSLER studies Compelling data on PCSK9 inhibition

Dr. Marc S Sabatine MD, Boston, describes the very compelling results of OSLER studies and the potential for PCSK9 inhibition to reduce major cardiovascular events through robust LDL-c reduction

News • 17-3-2015

More evidence for durability of efficacy and safety of PCSK9 inhibition

ACC 2015 Alirocumab Q4W can give sustained LDL-c lowering in some patients. Pooled analyses confirm safety of this PCSK9-antibody, also at very low LDL-c levels.
 
Literature • 19-3-2015 • Robinson et al., NEJM 2015

PCSK9 inhibitor produces considerable LDL-C reduction with fewer cardiovascular events

The ODYSSEY LONG TERM trial showed that alirocumab in addition to statins sustainably yielded a large reduction in LDL-c in patients at high CV risk and suggests that they experience fewer CV events.